This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Oct;64(10):3486; author reply 3486.

doi: 10.1002/art.34617.

Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al

Kyriakos A Kirou, Elena Gkrouzman, James M Chevalier, Surya V Seshan

PMID: 22777724
DOI: 10.1002/art.34617

Comment

Antiinflammatory strategies, not just B cell depletion, are required for optimal therapy for severe proliferative lupus nephritis: comment on the article by Rovin et al

Kyriakos A Kirou et al. Arthritis Rheum. 2012 Oct.

. 2012 Oct;64(10):3486; author reply 3486.

doi: 10.1002/art.34617.

Authors

Kyriakos A Kirou, Elena Gkrouzman, James M Chevalier, Surya V Seshan

PMID: 22777724
DOI: 10.1002/art.34617

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Rovin BH, et al. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. Arthritis Rheum. 2012. PMID: 22231479 Clinical Trial.

Similar articles

Response to 'Are steroids required for induction therapy and relapses in lupus nephritis?' by Abud-Mendoza et al.
Condon M. Condon M. Ann Rheum Dis. 2013 Dec;72(12):e30. doi: 10.1136/annrheumdis-2013-204331. Epub 2013 Sep 27. Ann Rheum Dis. 2013. PMID: 24078676 No abstract available.
Are steroids required for induction therapy and relapses in lupus nephritis?
Abud-Mendoza C, González-Amaro R. Abud-Mendoza C, et al. Ann Rheum Dis. 2013 Dec;72(12):e29. doi: 10.1136/annrheumdis-2013-204321. Epub 2013 Aug 13. Ann Rheum Dis. 2013. PMID: 23942867 No abstract available.
Rituximab, a viable alternative for induction therapy of active lupus nephritis.
Zhou XJ, Zhao MH, Zhang H. Zhou XJ, et al. Rheumatology (Oxford). 2014 Sep;53(9):1537-8. doi: 10.1093/rheumatology/keu152. Epub 2014 Apr 12. Rheumatology (Oxford). 2014. PMID: 24729446 No abstract available.
New and future therapies for lupus nephritis.
Appel GB. Appel GB. Cleve Clin J Med. 2012 Feb;79(2):134-40. doi: 10.3949/ccjm.78gr.11004. Cleve Clin J Med. 2012. PMID: 22301564 Review.
Treatment for refractory lupus nephritis: Rituximab vs triple target therapy.
Cervera R, Mosca M, Ríos-Garcés R, Espinosa G, Trujillo H, Bada T, Praga M. Cervera R, et al. Autoimmun Rev. 2019 Dec;18(12):102406. doi: 10.1016/j.autrev.2019.102406. Epub 2019 Oct 22. Autoimmun Rev. 2019. PMID: 31654743 Review. No abstract available.

See all similar articles

Cited by

CD20 antibody primes B lymphocytes for type I interferon production.
Xu D, Staedman A, Zhang L. Xu D, et al. PLoS One. 2013 Jun 18;8(6):e67900. doi: 10.1371/journal.pone.0067900. Print 2013. PLoS One. 2013. PMID: 23874371 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley